Pharmacoeconomic Evaluation of QiZheng XiaoTong Plaster Treating Acute Lumbar Sprain

Fei Xu,Liu Gordon,Yong Tang,Jinzhong Ma,Jinxue Li
2014-01-01
Abstract:Objective To evaluate cost-efectiveness and cost-utility of QiZheng XiaoTong plaster and Diclofenac Diethylamine Emulgel for the treatment of acute lumbar sprain,in order to provide evidence for clinical strategy choice.Methods From July 2012 to June 2013,295 patients with acute lumbar sprain were selected from five tertiary hospitals in Beijing,Shanghai,Guangzhou and Tongliao.152 patients are assigned to QiZheng XiaoTong plaster treatment group and 143 to Diclofenac Diethylamine Emulgel treatment group.Pain recovery time is chosen as the efectiveness indexes and the Quality adjusted Life years (QALYs) as utility index.Efectiveness,utility and cost of the two treatment schemes are compared with the method of cost-efectiveness analysis and cost-utility analysis.Results Compared with Diclofenac Diethylamine Emulgel treatment group, the pain recovery time of QiZheng XiaoTong plaster treatment group is significantly less(8.26 days vs.9.23 days,P<0.001).QiZheng XiaoTong plaster treatment group gains more QALYs (0.0362 vs. 0.0359,P = 0.597),but the cost is higher (308.52 Yuan vs.297.43 Yuan,P = 0.697).Cost-efectiveness analysis shows that the incremental cost-efectiveness ratio (ICER) is-11.43 Yuan/day,which means that reducing one additional day of pain recovery costs 11.43 Yuan more.Cost-utility analysis shows that the incremental cost-utility ratio(ICUR) was 36,966.67 Yuan/QALY,below the threshold of 115,000 Yuan/QALY suggested by WHO(3 times of GDP per capita).Conclusion In the treatment of acute lumbar sprain,QiZheng XiaoTong plaster is a highly cost-efective strategy for clinical promotion.
What problem does this paper attempt to address?